JP2024518163A5 - - Google Patents

Info

Publication number
JP2024518163A5
JP2024518163A5 JP2023568324A JP2023568324A JP2024518163A5 JP 2024518163 A5 JP2024518163 A5 JP 2024518163A5 JP 2023568324 A JP2023568324 A JP 2023568324A JP 2023568324 A JP2023568324 A JP 2023568324A JP 2024518163 A5 JP2024518163 A5 JP 2024518163A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
amino acid
product according
seq
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/072188 external-priority patent/WO2022236335A1/en
Publication of JP2024518163A publication Critical patent/JP2024518163A/ja
Publication of JP2024518163A5 publication Critical patent/JP2024518163A5/ja
Pending legal-status Critical Current

Links

JP2023568324A 2021-05-07 2022-05-06 TACI-Fc融合免疫調節タンパク質を用いた投薬および処置の方法 Pending JP2024518163A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163186027P 2021-05-07 2021-05-07
US63/186,027 2021-05-07
US202163239899P 2021-09-01 2021-09-01
US63/239,899 2021-09-01
US202163256505P 2021-10-15 2021-10-15
US63/256,505 2021-10-15
US202163278072P 2021-11-10 2021-11-10
US63/278,072 2021-11-10
US202263329325P 2022-04-08 2022-04-08
US63/329,325 2022-04-08
PCT/US2022/072188 WO2022236335A1 (en) 2021-05-07 2022-05-06 Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein

Publications (2)

Publication Number Publication Date
JP2024518163A JP2024518163A (ja) 2024-04-25
JP2024518163A5 true JP2024518163A5 (cg-RX-API-DMAC10.html) 2026-07-16

Family

ID=81851023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568324A Pending JP2024518163A (ja) 2021-05-07 2022-05-06 TACI-Fc融合免疫調節タンパク質を用いた投薬および処置の方法

Country Status (13)

Country Link
US (1) US20240279310A1 (cg-RX-API-DMAC10.html)
EP (1) EP4333869A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024518163A (cg-RX-API-DMAC10.html)
KR (1) KR20240019124A (cg-RX-API-DMAC10.html)
CN (3) CN119236057A (cg-RX-API-DMAC10.html)
AU (1) AU2022269139A1 (cg-RX-API-DMAC10.html)
CA (1) CA3216795A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003301A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023016161A2 (cg-RX-API-DMAC10.html)
IL (1) IL308336A (cg-RX-API-DMAC10.html)
MX (1) MX2023013114A (cg-RX-API-DMAC10.html)
PE (1) PE20240641A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022236335A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
US20260125451A1 (en) * 2022-08-29 2026-05-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fusion protein comprising taci polypeptide and use thereof
IL319997A (en) * 2022-10-04 2025-06-01 Alpine Immune Sciences Inc Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
WO2024114777A1 (zh) * 2022-12-02 2024-06-06 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗微小病变型肾病的方法
WO2024120458A1 (zh) * 2022-12-07 2024-06-13 荣昌生物制药(烟台)股份有限公司 TACI-Fc融合蛋白液体药物制剂
EP4748393A1 (en) * 2023-07-06 2026-05-27 RemeGen Co., Ltd. Method for treating anca-associated vasculitis using taci-fc fusion protein
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法
WO2026067736A1 (zh) * 2024-09-30 2026-04-02 盛禾(中国)生物制药有限公司 一种特异性结合bdca2的抗体及bdca2-taci抗体融合蛋白
WO2026122561A2 (en) 2024-12-03 2026-06-11 Otsuka America Pharmaceutical, Inc. Methods of treating sjögren's disease
WO2026153508A1 (en) * 2025-01-17 2026-07-23 Hansoh Bio Llc Polypeptide and fusion protein and use thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
EP0584266B1 (en) 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
WO1996009380A1 (en) 1994-09-23 1996-03-28 The University Of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
ATE197765T1 (de) 1994-10-03 2000-12-15 Us Gov Health & Human Serv Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
CN1348463A (zh) 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CZ303272B6 (cs) 1999-01-07 2012-07-11 Zymogenetics, Inc. Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトIgG4抗体
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
WO2007134326A2 (en) * 2006-05-15 2007-11-22 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
ES2681195T3 (es) * 2007-06-13 2018-09-12 Zymogenetics, Inc Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso
CN101323643B (zh) 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
AU2012211725A1 (en) * 2011-02-02 2013-08-29 Daiichi Sankyo Company, Limited Peptide library
WO2012125850A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Fc variants
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防
CN110903398B (zh) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
US10562954B2 (en) * 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
US12202882B2 (en) * 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Similar Documents

Publication Publication Date Title
RU2580012C2 (ru) Препарат антитела
EP3390444B1 (en) Anti-tl1a antigen binding proteins and uses thereof
ES2552954T3 (es) Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
US20200069797A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
ES2783448T3 (es) Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28
NZ719092A (en) Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
JP2024038308A (ja) 抗血液樹状細胞抗原2抗体の臨床使用のための医薬組成物及び投与レジメン
CN112105343A (zh) 抗-pd-1抗体组合物
CN102574920A (zh) 用依帕珠单抗治疗自体免疫和炎性疾病
IL308336A (en) Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
EP1933868A2 (en) Anti-cd3 antibody formulations
CN107249637A (zh) 用于治疗il‑6相关疾病的组合物
CN114630678A (zh) FcRn抗体及其使用方法
US20240075133A1 (en) Methods and compositions for reduction of immunogenicity
JP2025529796A (ja) Taciポリペプチドを含む融合タンパク質及びその使用
IL319997A (en) Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
TW202544038A (zh) 用於治療甲狀腺眼病的方法
US20240368249A1 (en) Fusion proteins for treating atopic dermatitis
TW202436340A (zh) 組合療法及相關方法
JP2024539751A (ja) 抗cd22抗体の水性製剤およびそれらの使用
WO2010081787A1 (en) IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
US20240052047A1 (en) Anti- il27r antibodies and methods of use thereof
WO2025185555A1 (en) Pharmaceutical compositions comprising ox40 targeting antibodies and uses thereof
TW202529803A (zh) 用於治療伴有多血管炎的嗜酸性球性肉芽腫病的IL-5R-α抗體